Profile data is unavailable for this security.
About the company
Zoetis Inc. is an animal health company. The Company is focused on the discovery, development, manufacture and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests and precision animal health. It has a diversified business, commercializing products across eight core species: dogs, cats and horses (companion animals) and cattle, swine, poultry, fish and sheep (livestock); and within seven major product categories: parasiticides, vaccines, dermatology, other pharmaceutical, anti-infectives, animal health diagnostics and medicated feed additives. The Company operates through two segments: the United States and International. Within each of these segments, it offers a diversified product portfolio for both companion animal and livestock customers. It directly markets its products in approximately 45 countries across North America, Europe, Africa, Asia, Australia and South America, and its products are sold in more than 100 countries.
- Revenue in USD (TTM)8.92bn
- Net income in USD2.34bn
- Incorporated2012
- Employees14.10k
- LocationZoetis Inc10 Sylvan WayPARSIPPANY 07054United StatesUSA
- Phone+1 (973) 822-7000
- Fax+1 (302) 655-5049
- Websitehttps://www.zoetis.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Biogen Inc | 9.67bn | 1.16bn | 28.78bn | 7.57k | 24.89 | 1.81 | 16.64 | 2.98 | 7.94 | 7.94 | 66.42 | 109.05 | 0.3723 | 1.23 | 4.60 | 1,277,675.00 | 4.46 | 12.53 | 5.07 | 14.83 | 75.54 | 83.04 | 11.97 | 26.93 | 1.48 | 2.87 | 0.2837 | 0.00 | -3.32 | -6.07 | -61.89 | -23.58 | -18.87 | -- |
| Zoetis Inc | 8.92bn | 2.34bn | 89.02bn | 14.10k | 38.47 | 17.96 | 31.29 | 9.98 | 5.11 | 5.11 | 19.42 | 10.94 | 0.6388 | 1.04 | 6.59 | 632,269.50 | 16.78 | 14.47 | 19.23 | 17.18 | 70.03 | 69.77 | 26.27 | 25.77 | 2.09 | 16.74 | 0.5696 | 26.89 | 5.74 | 7.96 | 10.88 | 11.13 | 16.71 | 24.37 |
| Bristol-Myers Squibb Co | 46.51bn | -6.54bn | 100.84bn | 34.10k | -- | 5.93 | 28.82 | 2.17 | -3.26 | -3.26 | 22.83 | 8.39 | 0.4944 | 4.07 | 4.98 | 1,363,900.00 | -6.94 | 3.05 | -9.03 | 3.76 | 76.18 | 76.13 | -14.04 | 7.69 | 1.02 | 14.60 | 0.7543 | 133.63 | -2.50 | 14.81 | 26.84 | 10.03 | 4.92 | 7.34 |
| Gilead Sciences, Inc. | 27.81bn | 1.05bn | 104.44bn | 18.00k | 102.42 | 5.72 | 27.55 | 3.76 | 0.8191 | 0.8191 | 22.20 | 14.67 | 0.4797 | 3.43 | 6.25 | 1,544,722.00 | 1.78 | 6.74 | 2.26 | 8.12 | 77.44 | 79.14 | 3.71 | 16.95 | 0.9546 | 9.36 | 0.562 | 81.22 | -0.6048 | 4.15 | 23.37 | 0.7436 | -8.74 | 5.64 |
| Pfizer Inc | 55.64bn | -2.59bn | 168.58bn | 88.00k | -- | 1.92 | 40.78 | 3.03 | -0.4643 | -0.4646 | 9.81 | 15.48 | 0.255 | 1.47 | 5.15 | 632,295.40 | -1.17 | 8.20 | -1.43 | 10.40 | 71.29 | 69.34 | -4.61 | 22.68 | 0.602 | -- | 0.4412 | 60.11 | -41.70 | 7.46 | -93.20 | -7.94 | 12.21 | 3.82 |
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 30 Jun 2024 | 39.19m | 8.65% |
| BlackRock Fund Advisorsas of 30 Jun 2024 | 23.04m | 5.09% |
| SSgA Funds Management, Inc.as of 30 Jun 2024 | 19.68m | 4.35% |
| State Farm Investment Management Corp.as of 30 Jun 2024 | 16.15m | 3.57% |
| AllianceBernstein LPas of 30 Jun 2024 | 14.97m | 3.31% |
| Geode Capital Management LLCas of 30 Jun 2024 | 10.24m | 2.26% |
| Managed Account Advisors LLCas of 30 Jun 2024 | 9.97m | 2.20% |
| Wellington Management Co. LLPas of 30 Jun 2024 | 8.91m | 1.97% |
| Polen Capital Management LLCas of 30 Jun 2024 | 7.05m | 1.56% |
| Capital Research & Management Co. (World Investors)as of 30 Jun 2024 | 6.78m | 1.50% |
